[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Algeria\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":423},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,50,79,104,144,181,208,236,263,296,326,360,385],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100652918","obesial-a-prospective-interventional-real-world-study-of-a-multidisciplinary-obesity-management-programme-100652918",false,"NCT07779343","OBESIAL: A Prospective Interventional Real-world Study of a Multidisciplinary Obesity Management Programme","OBESIAL","Inclusion Criteria:\n\n* Adults aged 18-65 years\n* BMI ≥30 kg\u002Fm²\n* Written informed consent obtained prior to enrolment\n\nExclusion Criteria:\n\n* Refusal to participate or inability to adhere to follow-up procedures\n* Pregnancy at enrolment\n* Severe or unstable comorbidities compromising safety or participation, including:\n\n  * Recent acute cardiovascular event (\\\u003C60 days)\n  * Active malignancy\n  * Severe unstable organic disease\n* Previous bariatric surgery\n* Obesity pharmacotherapy within the previous 90 days\n* Known contraindication to planned therapeutic options\n* Severe unstable psychiatric disorders\n* Genetic obesity or obesity secondary to uncontrolled endocrine disease\n\nExclusion Criteria During Follow-up\n\n* Pregnancy occurring during follow-up\n* Initiation of chronic treatment associated with weight gain","ALL","18 Years","65 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"NA","The OBESIAL (Obesity Structured Intervention in Algeria) study aims to evaluate the clinical, metabolic, and organisational impact of a structured multidisciplinary obesity care pathway implemented under real-world conditions.",[27,28,29,30],"Obesity Difficult Airway Airway Management","Obesity Adult Onset","Obesity and Cardiovascular Risk","Obesity Type 2 Diabetes Mellitus",[32,33,34,35,36],"obesity","adult obesity","multidisciplinary care","lifestyle interventions","GLP-1 receptor agonists","RECRUITING","2026-08-18",{"date":40,"type":41},"2026-08-21","ACTUAL",{"date":43,"type":41},"2026-01-22",{"date":45,"type":21},"2028-01-23",{"name":47,"class":48},"University of Health Sciences, Algeria","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100640507","essential-oils-for-urinary-symptoms-in-multiple-sclerosis-patients-100640507","NCT07599189","Essential Oils for Urinary Symptoms in Multiple Sclerosis Patients","Efficacy and Safety of Essential Oil Aromatherapy on Neurogenic Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis: A Randomized Single-Blind Placebo-Controlled Clinical Trial.","AROMA-MS","Inclusion Criteria:\n\n* Confirmed diagnosis of Multiple Sclerosis (any form)\n* Documented lower urinary tract symptoms defined by an Overactive Bladder Symptom Score (OABSS) ≥ 3 at screening\n* Age between 18 and 65 years\n* Willing and able to provide written informed consent\n* Capable of performing daily topical self-application of the study oil, or having a caregiver available to assist throughout the study period\n\nExclusion Criteria:\n\n* Active urinary tract infection confirmed by urine culture at screening\n* Pre-existing urological condition unrelated to Multiple Sclerosis (e.g., bladder cancer, benign prostatic hyperplasia, or interstitial cystitis)\n* Known allergy or hypersensitivity to essential oils, apricot kernel oil, lavender, or rosemary\n* Active skin lesions, wounds, or dermatological conditions on the lower abdomen at the intended site of application\n* Pregnancy, breastfeeding, or planning to become pregnant during the study period\n* Significant cognitive impairment preventing understanding of study procedures or completion of questionnaires\n* Current use of an indwelling urinary catheter or practice of intermittent self-catheterization",{"count":59,"type":21},60,[24],"The goal of this clinical trial is to learn if essential oil aromatherapy works to improve urinary symptoms in adults with multiple sclerosis. It will also learn about the safety of essential oil use in this population.\n\nThe main questions it aims to answer are:\n\n* Does essential oil aromatherapy reduce urinary urgency, frequency, and incontinence episodes in participants with multiple sclerosis?\n* What medical problems do participants have when using essential oil aromatherapy?\n\nResearchers will compare essential oil aromatherapy to a placebo (a look-alike neutral oil with no therapeutic properties) to see if essential oil aromatherapy works to improve urinary symptoms in multiple sclerosis patients.\n\nParticipants will:\n\n* Use essential oil aromatherapy or a placebo oil every day for 6 weeks\n* Complete a urinary symptom scales to record the frequency, urgency, and any leakage episodes each day\n* Fill out quality of life questionnaires at the beginning and end of the study",[63,64,65,66,67],"Multiple Sclerosis (MS)","Neurogenic Bladder Disorder","Urinary Incontinence (UI)","Urinary Urgency","Lower Urinary Tract Symptoms (LUTS)","NOT_YET_RECRUITING","2026-05-16",{"date":71,"type":41},"2026-05-20",{"date":73,"type":21},"2026-09",{"date":75,"type":21},"2027-03",{"name":77,"class":48},"University of Oran 1",2,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":87,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":49},"100615496","a-study-to-learn-about-the-c1-inhibitor-function-as-diagnosis-for-hereditary-angioedema-100615496","NCT07293364","A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema","A Prospective, Open- Label, Single-country (Algeria), Interventional Study to Assess Measurements of Functional C1-inhibitor Alone for Hereditary Angioedema Diagnosis: The AHAE Study","AHAE","Inclusion Criteria\n\n1. Adult and pediatric participants of both sexes (children over the age of 12 years).\n2. Participants providing a signed informed consent form (ICF), or parental consent for minors.\n3. Participants should also meet one of the 2 inclusion criteria below:\n\n   1. Participants with a high suspicion of bradykinin-mediated HAE, referred to the center. This includes recurrent episodes of nonpitting angioedema without urticaria or itching, lasting between 1 and 5 days, and non-responsive to antihistamine and corticosteroid treatments.\n   2. Family members (from 1st to 4th degree relatives) of known HAE participants.\n\nExclusion Criteria\n\n1. Confirmed diagnosis of HAE-C1INH-Type1 or HAE-C1INH-Type2.\n2. Angioedema with urticaria or itching (suggesting histaminergic etiology).\n3. Angioedema episodes lasting less than (\\\u003C)1 day or greater than (\\>)5 days (not consistent with bradykinin-mediated HAE).\n4. Any condition deemed unsuitable by the investigator that may interfere with study procedures or data integrity.","12 Years",{"count":89,"type":21},514,[24],"Hereditary angioedema (HAE) is a rare condition. It causes sudden swelling under the skin and inside the body, like in the belly, throat, or genitals. This swelling happens because of a temporary leak in blood vessels but does not cause itching or hives. HAE is classified based on the amount of a protein in the blood called C1-inhibitor (C1INH): HAE with normal C1INH levels and function (HAE-nC1INH) and HAE with deficiency in C1INH levels (HAE-C1INH-Type1) or dysfunction (HAE-C1INH-Type2). This study will focus on the practical use and accuracy of measuring the C1INH function alone to diagnose HAE-C1INH-Type1 and HAE-C1INH-Type2 compared to the tests used in normal clinical practice in Algeria.\n\nThe main goal of the study is to see how well a test focusing on the C1INH function alone works to diagnose HAE-C1INH as compared to the tests used in normal clinical practice (standard of care or SoC) in Algeria. Another aim is to determine a reference value (helps in determining the accuracy) of the C1INH function test. This study will also help to find out how many people who are thought to have HAE or who have family members with HAE actually get diagnosed and to gather participants' health background information, such as their age when they were diagnosed, what signs and symptoms they had, how long it took to get diagnosed, and how they were sent to the doctors or specialists who treated them.\n\nDuring the study all participants will undergo two different methods of HAE testing: the test focusing on the C1INH function alone and the SoC tests. Test results will be confirmed via a second test run for newly index cases or for discordant results, but participants with a test result of \"no HAE\" and positive cases recruited through family screening will not undergo a second confirmatory test. In case of discordant test results in the second round, participants will undergo a third confirmatory test round. Participants can visit the clinic up to three times during the study. No further follow up is planned for participants, even for those who are diagnosed with HAE.",[93],"Hereditary Angioedema (HAE)","2026-05-15",{"date":96,"type":41},"2026-05-19",{"date":98,"type":41},"2026-05-12",{"date":100,"type":21},"2027-06-12",{"name":102,"class":103},"Takeda","INDUSTRY",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":111,"minAge":112,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":78},"100634654","real-world-bicohort-observational-study-of-a-pertuzumab-biosimilar-in-the-treatment-of-breast-cancer-in-the-neoadjuvant-setting-and-in-first-line-metastatic-disease-100634654","NCT07542496","Real-world Bicohort Observational Study of a Pertuzumab Biosimilar in the Treatment of Breast Cancer: in the Neoadjuvant Setting and in First-line Metastatic Disease","PERTUREAL","Inclusion Criteria:\n\n* Age ≥ 19 years at the time of inclusion;\n* Histologically confirmed diagnosis of HER2-positive invasive breast cancer (IHC 3+ score or HER2 amplification by FISH\u002FCISH\u002FSISH);\n* Decision to initiate treatment with a pertuzumab biosimilar in the neoadjuvant setting (neoadjuvant cohort) or as first-line therapy in the metastatic setting (metastatic cohort), in accordance with local indications;\n* Treatment prescribed as part of routine clinical care (outside of a clinical trial);\n* Patient informed and having provided written informed consent.\n\nExclusion Criteria:\n\n* Treatment with pertuzumab in a therapeutic setting other than neoadjuvant or first-line metastatic (e.g., adjuvant, late recurrence beyond first-line, maintenance therapy alone, etc.);\n* Treatment administered as part of an interventional clinical trial;\n* History of severe allergy or known contraindication to pertuzumab;\n* Medical records unavailable or inability to ensure at least 6 months of minimal follow-up.","FEMALE","19 Years",{"count":114,"type":21},1000,"OBSERVATIONAL","The goal of this observational study is to describe the real-world utilization patterns of a pertuzumab biosimilar and to evaluate its clinical outcomes in patients with breast cancer in both neoadjuvant and metastatic settings. It also aims to assess pathological complete response (pCR), disease-free survival (DFS) in the neoadjuvant cohort, progression-free survival (PFS) in the metastatic cohort, overall survival (OS), treatment response, and safety and tolerability (adverse events according to CTCAE) across both cohorts.",[118,119],"Breast Cancer","Her 2 Positive Breast Cancer",[121,122,123,124,125,118,126,127,128,129,130,131,132,133,134],"Algerian Study","Real-world data","Algeria","Biosimilar","Pertuzumab","Cancer","Breast cancer in Algerian patients","HER2-Positive Breast Cancer","Neoadjuvant Therapy","Anti-HER2 Therapy","Cohort Study","Non-Interventional Study","HER2-Targeted Therapy","Observational Study","2026-04-14",{"date":137,"type":41},"2026-04-21",{"date":139,"type":41},"2026-01-15",{"date":141,"type":21},"2027-01-15",{"name":143,"class":48},"Société Algérienne de Formation et Recherche en Oncologie",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":151,"minAge":112,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":154,"conditions":155,"keywords":162,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":180},"100630230","study-of-the-epidemiological-clinical-diagnostic-and-therapeutic-characteristics-of-prostate-cancers-in-algeria-100630230","NCT07484971","Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria","CLIQQC","Inclusion Criteria:\n\n* Patients aged 19 years and older.\n* Diagnosis of prostate cancer confirmed histologically and\u002For biologically.\n* Patients followed in the participating oncology departments.\n* Written informed consent obtained.\n\nNon Inclusion Criteria:\n\n* Histological types other than carcinoma\n* Secondary tumors\n* Participation in an interventional study","MALE",{"count":153,"type":21},2000,"The goal of this observational study is to describe the demographic, epidemiological, clinical, and outcome characteristics of patients with prostate cancer.\n\nIt also aims to analyze the diagnostic approaches and management strategies used in the care of these patients in Algeria.",[156,157,158,159,160,161],"Prostate Cancer","Prostate Cancer (Diagnosis)","Prostate Cancer (Post Prostatectomy)","Prostate Cancer Patients Treated by Radiotherapy","Prostate Cancer Metastatic","Prostate Cancer (Adenocarcinoma)",[163,164,156,165,134,166,167,168,169,170,171,172,122,123,121],"oncology","patient outcome","Prostate Cancer in Algerian patients","Retrospective data","Treatment strategies","Diagnostic approaches","Clinical characteristics","Epidemiological data","Demographic data","Cross-sectional study",{"date":174,"type":41},"2026-04-17",{"date":176,"type":41},"2025-07-21",{"date":178,"type":21},"2026-07-21",{"name":143,"class":48},24,{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":112,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":189,"conditions":190,"keywords":194,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":207},"100629933","study-of-the-epidemiological-clinical-diagnostic-and-therapeutic-characteristics-of-gastric-cancers-in-algeria-100629933","NCT07481110","Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Gastric Cancers in Algeria","ECLIPSE-CG","Inclusion Criteria:\n\n* Patients aged 19 years and older\n* Histologically confirmed diagnosis of gastric cancer\n* Patients followed in the participating oncology departments\n* Informed consent obtained\n\nNon Inclusion Criteria:\n\n* Histological types other than carcinoma (e.g., GIST, lymphoma, sarcoma, etc.).\n* Secondary gastric tumors\n* Participation in an interventional study",{"count":114,"type":21},"The goal of this observational study is to describe the demographic, epidemiological, clinical, and outcome characteristics of patients with gastric cancer.\n\nIt also aims to analyze the diagnostic approaches and management strategies used in the care of these patients in Algeria.",[191,192,193],"Gastric Cancer","Gastric (Stomach) Cancer","Gastric Cancer (Diagnosis)",[191,195,196,197,198,166,167,168,169,170,171,172,122,123,121],"Gastric cancer in Algerian patients","Observational study","Patient outcomes","Oncology","2026-03-25",{"date":201,"type":41},"2026-03-27",{"date":203,"type":41},"2025-08-05",{"date":205,"type":21},"2026-08-05",{"name":143,"class":48},15,{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":215,"sex":16,"minAge":17,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":219,"conditions":220,"keywords":222,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":49},"100620402","oral-and-salivary-biomarkers-associated-with-stroke-100620402","NCT07357155","Oral and Salivary Biomarkers Associated With Stroke","An Observational Study of Oral and Salivary Biomarkers Associated With Stroke","Inclusion Criteria:\n\n* Adults aged 18 to 90 years.\n* Patients diagnosed with stroke (ischemic or hemorrhagic) confirmed by clinical and imaging criteria for the stroke group.\n* Healthy volunteers without a history of stroke or cerebrovascular disease for the control group.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* inflammatory disease at the time of sampling.\n* Chronic autoimmune or malignant disease.\n* Recent major surgery or trauma within the last 3 months.\n* Pregnancy or breastfeeding.\n* Inability or refusal to provide saliva samples.",true,"90 Years",{"count":218,"type":21},120,"This observational study aims to explore the association between oral and salivary biomarkers and stroke. The study will include adult participants diagnosed with stroke and will analyze clinical, oral, and salivary parameters. The objective is to improve understanding of potential links between oral health, salivary biomarkers, and cerebrovascular disease. No experimental intervention will be performed.",[221],"Stroke",[221,223,224,225,196],"Oral health","Salivary biomarkers","Cerebrovascular disease","2026-02-02",{"date":228,"type":41},"2026-02-05",{"date":230,"type":21},"2026-03-20",{"date":232,"type":21},"2026-12",{"name":234,"class":235},"University Hospital Center (CHU) of Constantine, Algeria","OTHER_GOV",{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":242,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":111,"minAge":17,"maxAge":244,"enrollmentInfo":245,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":247,"conditions":248,"keywords":251,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":78},"100604330","pregnancies-before-the-diagnosis-of-systemic-lupus-erythematosus-100604330","NCT07148115","Pregnancies Before the Diagnosis of Systemic Lupus Erythematosus","Pregnancy Outcomes Prior to a Systemic Lupus Erythematosus Diagnosis","PREDILUP","Inclusion criteria:\n\n* Women of childbearing age with a history of at least one pregnancy\n* Pregnancy occurred before the diagnosis of LES.\n* LES was diagnosed after at least one pregnancy.\n* The subject is classified as having LES according to the 1997 ACR or EULAR 2019 criteria.\n\nExclusion criteria:\n\nLES was previously diagnosed prior to any conception.","55 Years",{"count":246,"type":21},50,"This is an observational, monocentric, retrospective cohort study. Its primary objective is to examine maternal and foetal outcomes in pregnancies that occurred before the diagnosis of systemic lupus erythematosus (SLE) in a group of female participants who were subsequently diagnosed with the condition.",[249,250],"Pregnancy Complications","SLE",[252,250,253],"Pregnancy","Obstetrical events","2025-12-26",{"date":256,"type":41},"2025-12-31",{"date":258,"type":41},"2025-01-01",{"date":260,"type":21},"2026-04-30",{"name":262,"class":48},"University of Algiers",{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":271,"targetDuration":273,"studyType":115,"phases":4,"briefSummary":274,"conditions":275,"keywords":280,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":295},"100605389","alg-lungcancerregistry-safro2202-100605389","NCT07161882","ALG-LungCancerRegistry (SAFRO2202)","Observational Study of the Epidemiological, Clinical, and Diagnostic Profile, Treatment Patterns, and Outcomes of Lung Cancer.","SAFRO2202","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Histologically confirmed diagnosis of lung cancer (NSCLC, SCLC, or carcinoid tumor)\n* Diagnosed at the time of inclusion or within the 12 previous months\n* Fully managed (diagnosis, treatment, and follow-up) in an oncology or pulmonology department of one of the 21 participating public\u002Funiversity hospitals\n* Signed informed consent obtained\n\nExclusion Criteria:\n\n* Prior enrollment in this study\n* Participation in an interventional clinical trial",{"count":272,"type":21},3750,"12 Months","SAFRO 2202 ALG-Lung Cancer Registry is a prospective, multicenter, non-interventional observational study conducted across 21 public and university hospitals in Algeria. The objective is to characterize the epidemiological, clinical, pathological, molecular, and therapeutic features of patients diagnosed with lung cancer, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and carcinoid tumors.\n\nEligible participants are adults aged 18 years or older, diagnosed at the time of inclusion or within the previous 12 months, and fully managed in oncology or pulmonology departments. Data are collected during routine clinical care and recorded in a secure electronic case report form (eCRF). No protocol-mandated interventions or study-specific visits are required.\n\nThe study plans to enroll approximately 1,500 patients per year over a 30-month period. Primary outcomes include demographic and clinical profiles, tumor histology, molecular markers, staging at diagnosis, and treatment strategies (surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy). Secondary outcomes include treatment-related toxicities, objective response rate (ORR), progression-free survival (PFS), time to treatment discontinuation (TTD), and overall survival (OS).\n\nThe findings from this registry will provide real-world evidence to support national health planning, improve lung cancer management, and guide future clinical and public health initiatives in Algeria.",[276,277,278,279],"Lung Neoplasms","Carcinoma, Non-Small-Cell Lung","Carcinoma, Small Cell","Carcinoid Tumor",[281,282,279,283,284,285,123],"Lung Cancer","Non-Small Cell Lung Cancer","Treatment Outcomes","Drug-Related Side Effects","Registries","2025-09-12",{"date":288,"type":41},"2025-09-16",{"date":290,"type":41},"2025-06-01",{"date":292,"type":21},"2027-12",{"name":294,"class":48},"Société Algérienne de Formation et de Recherche en Oncologie",21,{"id":297,"slug":298,"hasResults":11,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":302,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":111,"minAge":112,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":306,"conditions":307,"keywords":309,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":49},"100605720","efficacy-of-neoadjuvant-subcutaneous-trastuzumab-pertuzumab-in-algerian-women-with-locally-advanced-her2-positive-breast-cancer-100605720","NCT07166185","Efficacy of Neoadjuvant Subcutaneous Trastuzumab-Pertuzumab in Algerian Women With Locally Advanced HER2 Positive Breast Cancer","Evaluation of the Efficacy of Subcutaneous Trastuzumab-Pertuzumab Combination in Neoadjuvant Treatment of Non-Metastatic HER2-Positive Breast Cancer in Algerian Women","NEOTRAPSCAL","Inclusion Criteria:\n\n* Female participants aged 19 years or older.\n* Histologically confirmed HER2-positive breast cancer (by immunohistochemistry and\u002For in situ hybridization), non-metastatic.\n* Candidate for neoadjuvant therapy according to local clinical practice.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.\n* Left ventricular ejection fraction (LVEF) ≥ 50%.\n* Signed written informed consent.\n\nExclusion Criteria:\n\n* Evidence of distant metastases.\n* Prior anti-HER2 therapy.\n* Known contraindications to trastuzumab or pertuzumab.\n* Pregnancy or breastfeeding.\n* Disease progression during neoadjuvant treatment (if already started).\n* Refusal of surgery.\n* Withdrawal of consent.",{"count":305,"type":21},70,"This study aims to find out how effective and well-tolerated the subcutaneous form of trastuzumab-pertuzumab (known as Phesgo) is when given before surgery (neoadjuvant treatment) to Algerian women with early stage, HER2-positive breast cancer.\n\nThe study will take place in three oncology centers in Algeria (Blida, Aïn Defla, Médéa) and include around 70 adult women diagnosed with non-metastatic HER2-positive breast cancer. Participants will receive Phesgo along with standard chemotherapy over about 18 weeks, followed by surgery.\n\nThe main goal is to measure how many women achieve complete destruction of invasive cancer in the breast and nearby lymph nodes (pathological complete response, pCR). We will also look at other outcomes such as how many women can keep their breast, any side effects, quality of life, satisfaction with treatment, and factors that might predict response.\n\nResults from this real-world study will help assess whether Phesgo can simplify treatment delivery, reduce hospital burden, and improve care access in Algeria where healthcare resources are often stretched.",[308],"Non Metastatic HER2 Positive Breast Cancer",[310,311,312,313,314,315,316],"HER2 positive","Breast cancer","non metastatic","Neoadjuvant therapy","Algerian women","Subcutaneous trastuzumab-pertuzumab","pathologic complete response","2025-09-03",{"date":319,"type":41},"2025-09-10",{"date":321,"type":41},"2025-03-01",{"date":323,"type":21},"2025-12",{"name":325,"class":48},"Blida 1 University",{"id":327,"slug":328,"hasResults":11,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":332,"eligibilityCriteria":333,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":334,"targetDuration":336,"studyType":115,"phases":4,"briefSummary":337,"conditions":338,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":359},"100454682","autoinflammatory-disease-alliance-registry-aida-100454682","NCT05200715","AutoInflammatory Disease Alliance Registry (AIDA)","Development of an International Multicenter Registry of Patients With Monogenic and Polygenic Autoinflammatory Diseases Aimed at Clinical and Therapeutical Data Collection and Analysis","AIDA","Inclusion Criteria:\n\n* to be diagnosed with a monogenic AID according to the clinical phenotype and the detection of a confirmative genotype;\n* to be diagnosed with clinical familial Mediterranean fever or Behçet's disease or Still disease or PFAPA syndrome or Schnitzler's disease or CRMO according to the corresponding clinical diagnostic and\u002For classification criteria;\n* to be diagnosed with undifferentiated systemic AID;\n* to be diagnosed with non-infectious uveitis according to the standardization for uveitis nomenclature (SUN) criteria;\n* to be diagnosed with anterior or posterior non-infectious scleritis;\n* to be diagnosed with spondyloarthritis according to ASAS and\u002For New York criteria;\n* to be diagnosed with Castleman disease;\n\nExclusion Criteria:\n\n\\- informed consent\u002Fassent not provided by the patient and\u002For his\u002Fher legal representative.",{"count":335,"type":21},3500,"10 Years","Autoinflammatory diseases (AID) are clinical entities characterized by recurrent inflammatory attacks in absence of infection, neoplasm or deregulation of the adaptive immune system. Among them, hereditary periodic syndromes, also known as monogenic AID, represent the prototype of this disease group, caused by mutations in genes involved in the regulation of innate immunity, inflammation and cell death. Based on recent experimental acquisitions in the field of monogenic AID, several immunologic disorders have been reclassified as polygenic\u002Fmultifactorial AID, sharing pathogenetic and clinical features with hereditary periodic fevers. This has paved the way to new treatment targets for patients suffering from rare diseases of unknown origin, including Behçet's disease, Still disease, Schnitzler's disease, PFAPA (periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis) syndrome, chronic recurrent multifocal osteomyelitis (CRMO), non-infectious uveitis and scleritis. Gathering information on such rare conditions is made difficult by the small number of patients, along with the difficulty of obtaining an accurate diagnosis in non-specialized clinical settings.\n\nIn this context, the AIDA project promotes international collaboration among clinical centres to develop a permanent registry aimed at collecting demographic, genetic, clinical and therapeutic data of patients affected by monogenic and polygenic AID, in order to expand the current knowledge of these rare conditions.",[339,340,341,342,343,344,345,346,347,348,349],"Hereditary Autoinflammatory Diseases","Schnitzler Syndrome","Behcet Syndrome","PFAPA Syndrome","Still Disease","Autoinflammatory Syndrome, Unspecified","Uveitis","Scleritis","Vexas Syndrome","Spondyloarthritis (SpA)","Castleman Disease","2025-07-07",{"date":352,"type":41},"2025-07-10",{"date":354,"type":41},"2020-08-06",{"date":356,"type":21},"2030-08-06",{"name":358,"class":48},"University of Siena",112,{"id":361,"slug":362,"hasResults":11,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":366,"eligibilityCriteria":367,"healthyVolunteers":11,"sex":111,"minAge":17,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":22,"phases":370,"briefSummary":372,"conditions":373,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":384},"100453865","phase-2-prediction-of-treatment-efficacy-of-the-combination-of-palbociclibletrozole-or-anastrozole-in-first-line-metastatic-women-with-luminal-her2-negative-advanced-breast-cancer-using-infrared-laser-spectroscopy-analysis-on-liquid-biopsies-100453865","NCT05190094","Prediction of Treatment Efficacy of the Combination of Palbociclib\u002F(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.","Multicenter, First-line Metastatic Open-label Prospective Phase II Trial Evaluating the Combination of Palbociclib (CDK 4\u002F6 Inhibitor) and Hormone Therapy (Letrozole or Anastrozole) in Women With Luminal, HER2 Negative Advanced Breast Cancer: Evaluation of the Prediction of Individual Treatment Efficacy Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies (Quantum Optics).","ICRG0201","Inclusion Criteria:\n\nTo be enrolled in the study, patients should meet the following inclusion criteria:\n\n1. Written informed consent before beginning specific protocol procedures including expected cooperation of the patients for the treatment and follow-up must be obtained and documented according to the local regulatory requirements.\n2. Postmenopausal women or pre\u002Fperi-menopausal women with Surgical oophorectomy (preferred) or Analogs of LHRH.\n3. Performance status \\\u003C 3 (according to WHO criteria).\n4. Histologically confirmed breast cancer (Luminal A or B).\n5. Estrogen Receptor positive (ER \\> 1%).\n6. HER2 negative (score 0 or 1 by immunochemistry), FISH negative if IHC score 2.\n7. Clinical stage IIIb \\& IV.\n8. Either:\n\n   1. Women with De novo advanced luminal HER2 negative advanced breast cancer without other prior systemic treatment for advanced disease.\n   2. Women with luminal HER2 negative advanced breast cancer either with secondary resistance (relapse after 2 years of adjuvant hormone therapy or within 12 months of completion of adjuvant HT) or sensitivity to adjuvant HT (relapse \\> 12 months after completion of adjuvant HT).\n9. Measurable or evaluable disease.\n10. Hematology:\n\n    * Neutrophil count ≥ 1.5 G\u002FL,\n    * Platelet count ≥ 100 G\u002FL,\n    * Leucocyte count \\> 3.0 G\u002FL,\n    * Hb\\> 9g\u002Fdl.\n11. Hepatic function:\n\n    * Total bilirubin ≤ 1.5 times the upper normal limit (UNL),\n    * ASAT ≤ 2.5xUNL,\n    * ALAT ≤ 2.5xUNL,\n    * Alkaline phosphatase ≤ 2.5 times the upper normal limit (UNL).\n12. Renal function:\n\n    • Serum creatinine ≤1.5xUNL (and if Serum creatinine \\>1.5xUNL, creatinine clearance ≥40 mL\u002Fmin),\n13. Metabolic function:\n\n    • Serum calcium ≥ lower limit of normal.\n14. Negative pregnancy test (urine or serum) within 7 days before registration for all women of childbearing potential. Patients of childbearing potential must implement adequate non-hormonal contraceptive measures during study treatment.\n15. Patients with negative Human Immunodeficiency Virus (HIV) and\u002For Hepatitis B and\u002For Hepatitis C results.\n\nExclusion Criteria:\n\nTo be enrolled in the study, patients should meet the following exclusion criteria:\n\n1. Male patients.\n2. HER2 positive tumors or unknown HR\u002FHER2 status.\n3. Triple-negative Breast Cancer (ER\\\u003C1%).\n4. Pregnant or breast-feeding women, or those who plan to become pregnant within 6 months post-treatment.\n5. No willingness to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months post-treatment.\n6. Any form of breast cancer other than those described in the inclusion criteria, particularly inflammatory and\u002For loco-regional disease (stages I, II \\& IIIa).\n7. Non-evaluable tumor.\n8. Bilateral breast cancer.\n9. Patients with a history of other cancer, except in situ cervical cancer or baso-cellular skin cancer, considered cured.\n10. Patient has another disease, which is deemed incompatible with the inclusion in the protocol.\n11. Heart, kidney, medullary, respiratory or liver failure.\n\n    * Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) at baseline.\n    * History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease at baseline,\n    * Acute urinary infection, ongoing hemorrhagic cystitis at baseline.\n12. Uncontrolled diabetes.\n13. Symptomatic or progressive disorder of the central nervous system (CNS) at baseline.\n14. Patients with positive Human Immunodeficiency Virus (HIV) and\u002For Hepatitis B and\u002For Hepatitis C results.\n15. Significant psychiatric abnormalities.\n16. History of hypersensitivity to studied treatment or excipients.\n17. Known previous or ongoing abuse of narcotic drug, other medication or alcohol.\n18. Any investigational agent within 30 days before initiation of study treatment.\n19. Patient unwilling or unable to comply with study requirements.",{"count":369,"type":21},80,[371],"PHASE2","This study is a multicenter, international, open-label phase II study. Based on inclusion\u002Fexclusion criteria, eligible pre and postmenopausal patients with newly diagnosed metastatic luminal hormone receptor-positive and HER2 negative breast cancer, will be prospectively treated with a standard combination of hormone therapy (Letrozole or Anastrozole) and Palbociclib. This combination will continue until progression. Treatment response will be evaluated every three months using clinical and radiological assessments (Revised RECIST guidelines).\n\nPatients will undergo serial liquid biopsies (blood tests) for plasma molecular fingerprinting by the Quantum Optics technology. This study will be the first program exploring the adjunction of the Quantum Optics technology on liquid biopsies to define individual 'molecular fingerprinting profiles' to predict the individual therapeutic effects of Palbociclib combined with Aromatase Inhibitors (AI) (plus ovarian function suppression (OFS) for pre\u002Fperi-menopausal patients) in luminal hormone receptor-positive and HER2 negative advanced breast cancer. Batteries of algorithmic tests will integrate the variables obtained by Quantum Optics (to evaluate the efficacy or not of the combination of Palbociclib + Aromatase Inhibitors (AI) ). This approach introduces the concept of singularity to break from the classic idea of \"one size fits all\".",[374],"Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer","2025-05-04",{"date":377,"type":41},"2025-05-07",{"date":379,"type":41},"2022-12-20",{"date":381,"type":21},"2026-06",{"name":383,"class":48},"International Cancer Research Group, United Arab Emirates",7,{"id":386,"slug":387,"hasResults":11,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":391,"eligibilityCriteria":392,"healthyVolunteers":215,"sex":111,"minAge":4,"maxAge":4,"enrollmentInfo":393,"targetDuration":4,"studyType":22,"phases":395,"briefSummary":397,"conditions":398,"keywords":406,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":49},"100582190","phase-1-impact-of-chromium-supplementation-on-glucido-lipidic-metabolism-oxidative-stress-and-inflammatory-state-in-patients-with-gestational-diabetes-100582190","NCT06860087","Impact of Chromium Supplementation on Glucido-lipidic Metabolism, Oxidative Stress and Inflammatory State in Patients with Gestational Diabetes","Impact of Chromium Supplementation on Glucido-lipidic Metabolism, Oxidative Stress and Inflammatory State in Pregnant Women with Gestational Diabetes Mellitus","Cr and GDM","Inclusion Criteria:\n\n* Healthy pregnant women:\n\n  * Whose their gestational age is 28 weeks\n  * They have no pathology or complication associated with their pregnancy.\n* Pregnant women with gestational diabetes mellitus:\n\n  * They will be selected according to the criteria of the one-step method for screening for gestational diabetes mellitus established by the WHO.\n  * They have no other pathology or complication associated with pregnancy.\n  * They are subjected to insulin therapy and a low-calorie diet, rich in protein, fiber and beneficial lipids (they will all asked to keep their medical treatment prescribed by their doctor).\n* All women involved in this study will be systematically supplemented with 60 mg\u002Fd iron and 400 mg\u002Fd vitamin B9 during pregnancy as recommended by WHO.\n\nExclusion Criteria:\n\n* Pregnant women with unrecognized diabetes, type I or type II, will not be involved in this study.\n* Pregnant women who were supplemented before one month or during pregnancy, or who will need other micronutrient supplements during the study to avoid their influence on the results.\n* Pregnant women who develop other health complications will be removed from the study and replaced by others.\n* Women with gestational diabetes mellitus who were unable to complete chromium supplementation up to 6 weeks will be excluded from the study and replaced by others.",{"count":394,"type":21},200,[396,371],"PHASE1","Our study aims to explore the influence of dietary chromium supplementation in the form of chromium picolinate, at different doses (200 µg and 400 µg per day), on the health of pregnant women with gestational diabetes. This study will also provide more information on the safety of this type of supplementation during pregnancies complicated by gestational diabetes mellitus.\n\nThe main questions it aims to answer are:\n\n* Does chromium supplementation at various doses in women with gestational diabetes mellitus truly influence their glucido-lipidic metabolism, oxidative\u002Fantioxidant balance, and inflammatory state? If so, is it beneficial or detrimental?\n* If this supplementation is beneficial, which dose is the most appropriate?\n* Do these types of supplementation have any side effects on the health of the mother and fetus? The participants will take chromium supplements for 6 weeks (supplemented groups) while the control participants will not take them (healthy and diabetic control groups).\n\nChromium-supplemented participants will undergo a medical check-up every 02 weeks to closely monitor their health status and detect any potential side effects at an early stage.\n\nResearchers will compare the biochemical profile, oxidative stress status, and inflammation markers between chromium-supplemented and non-supplemented participants to assess the impact of this trace element.\n\nResearchers will compare the effects of chromium supplements at different doses with each other.",[399,400,401,402,403,404,405],"Gestational Diabetes Mellitus (GDM)","Oxidative Stress","Inflammatory Status","Insulin Resistance","Leptin Resistance","Glucose Metabolism Disorder","Lipid Metabolism Disorders",[407,408,409,410,411,412,413,414],"Inflammatory status markers","Oxidative stress markers","Glucido-lipidic metabolism","HOMA-IR","Leptin level","Lipid profile","Fasting plasma glucose","Insulin level",{"date":416,"type":41},"2025-03-05",{"date":418,"type":21},"2025-05",{"date":420,"type":21},"2026-01",{"name":422,"class":48},"University of Kasdi Merbah",""]